Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 114
- Registration Number
- NCT05520619
- Locations
- 🇨🇳
Mian Xi, Guangzhou, Guangdong, China
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05519865
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT05515315
- Locations
- 🇨🇳
Ye zai sheng, Fuzhou, Fujian, China
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-09-11
- Target Recruit Count
- 112
- Registration Number
- NCT05511623
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT05494762
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-10-21
- Target Recruit Count
- 29
- Registration Number
- NCT05493683
- Locations
- 🇨🇳
Changzhou NO.2 People's Hospital, Changzhou, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT05479240
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Won Seog Kim
- Target Recruit Count
- 38
- Registration Number
- NCT05477264
- Locations
- 🇰🇷
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 116
- Registration Number
- NCT05468242
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, China
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Target Recruit Count
- 17
- Registration Number
- NCT05469061
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.